This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Stimulant Drug Treatment of Attention-Deficit Hyperactivity Disorder (AD/HD), Inattentive Type

This study has been completed.
National Institute of Mental Health (NIMH)
Information provided by:
Icahn School of Medicine at Mount Sinai Identifier:
First received: January 15, 2009
Last updated: NA
Last verified: January 2009
History: No changes posted
The purpose of this study is to compare the response to methylphenidate treatment of children with two different subtypes of ADHD.

Condition Intervention
ADHD Drug: methylphenidate Drug: Placebo

Study Type: Interventional
Study Design: Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Stimulant Drug Treatment of AD/HD, Inattentive Type

Resource links provided by NLM:

Further study details as provided by Icahn School of Medicine at Mount Sinai:

Primary Outcome Measures:

Secondary Outcome Measures:

Enrollment: 25
Study Start Date: October 2001
Study Completion Date: February 2005
Primary Completion Date: February 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Drug: Placebo
Experimental: 2
Drug: methylphenidate
(15 mg daily), medium (25 mg daily) and high (40 mg daily)

Detailed Description:
The Inattentive subtype (IN) of Attention-Deficit/Hyperactivity Disorder was newly defined in DSM-IV (1994). Recent epidemiological studies suggest that IN is at least as common and as impairing academically and socially as the more commonly recognized Combined type (CB). However, little is known about the etiology, course and outcome, or treatment of the IN type. Notably, although stimulant drugs are commonly used clinically to treat the disorder, there have been no systematic studies of its efficacy in the IN subtype. Differences between the IN and CB subtypes in behavioral phenotype, as well as in gender ratio, age of onset, and comorbidity suggest there may be critical differences in neurobiology, which may have relevance for response to drug treatments. The lack of data concerning stimulant drug efficacy in the IN type thus constitutes an important issue from the perspective of public health and quality of care. The proposed research is responsive to the current RFA in that it will study the efficacy of an established treatment (stimulants) in a new patient population (the IN subtype). A second specific aim is to test a hypothesis, emerging from a review of the literature, of divergence between dose-response curves for effects on activity and attention. We predict that the dose that optimizes performance on ratings of hyperactivity-impulsivity will be lower than that which optimizes performance on ratings of academic function and on the neuropsychological tests. We will similarly examine whether differences in dose-response curves for specific functions extend to differences between subtypes in optimal dose. The final aim of the current study is to compare the IN and CB subtypes with respect to selected measures of neurocognitive function on placebo and in response to drug treatment. We predict that the IN subtype will perform more poorly on measures of spatial orienting and stimulus encoding, whereas the CB subtype will show greater deficits on measures of cognitive inhibitory control, and that both types of cognitive deficit will respond to drug treatment.

Ages Eligible for Study:   7 Years to 13 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:Inattentive Subtype:

Inclusion Criteria:

  1. A diagnosis on the structured DISC interview conducted with the parent, of ADHD, Predominantly Inattentive Type.
  2. Ratings by parent and by teacher corresponding to a total score above the 93rd percentile (i.e. more than 1.5 SD above the mean) on the scale of "DSM-IV Inattention" on the current Conners Parent (or Teacher) Rating Scale - Long Form. The items on this scale are the inattention symptom criteria from the DSM-IV, each of which the informant is asked to rate in severity on a 4-point scale ranging in severity from 0 ("not at all") to 3 ("very much"). A score above the 93th percentile indicates that the child's score equals or exceeds that for 93% of other children of the same age (within 2 years) and gender.

Exclusion Criteria:

(a) Scores more than 1 SD (84th percentile) above the mean on the DSM-IV-Hyperactive-Impulsive scale on the Conners Parent or Teacher Rating Scales-Long Form.

Combined Subtype:

Inclusion Criteria:

  1. A diagnosis of ADHD, Combined type on the structured DISC interview with the parent.
  2. Ratings by parent and teacher each corresponding to a total score above the 93rd percentile (i.e. more than 1.5 SD above the mean) on the scale of "DSM-IV attention" on the current Conners Parent (Teacher) Rating Scales - Long Form.
  3. Ratings by parent and teacher each corresponding to a total score above the 93rd percentile (i.e. more than 1.5 SD above the mean) on the scale of "DSM-IV Hyperactive-Impulsive" symptoms on the current Conners Parent (Teacher) Rating Scales - Long Form.

Both Groups:

Inclusion Criterion: The child's school must agree to administer medication at mid-day and to allow the teacher to complete the requisite behavior ratings.

Exclusion Criteria:

  1. WISC-III full-scale IQ less than 80.
  2. Major acute or chronic medical condition, including sensory loss, and neurological disorder, or any medical condition that would preclude the use of stimulant medication.
  3. Comorbidity: The study rationale for inclusion/exclusion of comorbid psychological/psychiatric conditions is as follows: children for whom the study treatment is contraindicated, or for whom treatment not provided in the study is required immediately, will not be entered in the trial. Thus, as an example, comorbid depression or anxiety disorder is permitted provided immediate treatment of the depressive or anxiety disorder is not required. Tic disorders of mild to moderate severity, and stable, would be eligible for inclusion, as this would not constitute a contraindication to receiving stimulants. However, children with pronounced or unstable tics would not be eligible for the trial.

    Children with any of the following conditions will be excluded from the study: psychosis, any pervasive developmental disorder, and bipolar disorder. Thus children will be permitted in the study if they have a comorbid learning disability, oppositional defiant disorder, or conduct disorder. The Wechsler Individual Achievement Tests will be administered in order that we can characterize our sample with respect to the presence of comorbid learning disabilities.

  4. Concomitant medications: Systemically absorbed medication will be exclusionary, while non-systemically absorbed medications will generally be permitted. Children who have taken any experimental medication in the past month will be excluded. Any prior psychotropic medication must have a suitable washout period of at least 4 half-lives before assessment can begin (generally a minimum of 2 weeks; up to 4 weeks for fluoxetine). Children taking methylphenidate at the time of inquiry may be withdrawn from medication only if treatment response is less than optimal and a re-evaluation is deemed clinically necessary. Children taking other psychotropic medication may be discontinued, provided their prescribing physician is in agreement with this plan, and provided there is clinical indication for doing so (i.e., either inadequate response, adverse effects or problematic time-action properties).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00824317

United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
National Institute of Mental Health (NIMH)
Principal Investigator: Mary Solanto Icahn School of Medicine at Mount Sinai
  More Information

Responsible Party: Mary Solanto, Associate Professor, Mount Sinai School of Medicine Identifier: NCT00824317     History of Changes
Other Study ID Numbers: 00-0394
R21MH062945 ( U.S. NIH Grant/Contract )
Study First Received: January 15, 2009
Last Updated: January 15, 2009

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents processed this record on September 21, 2017